Pharmaceutical Sterility Testing Market Report 2026

The pharmaceutical sterility testing market size has grown exponentially in recent years. It will grow from $1.68 billion in 2025 to $2.07 billion in 2026 at a compound annual growth rate (CAGR) of 23.7%. The growth in the historic period can be attributed to increasing need for sterile pharmaceutical products, limited availability of advanced testing laboratories, growing pharmaceutical production and biologics pipelines, reliance on conventional sterility testing methods, rising awareness of quality control standards.

The pharmaceutical sterility testing market size is expected to see exponential growth in the next few years. It will grow to $4.91 billion in 2030 at a compound annual growth rate (CAGR) of 24.1%. The growth in the forecast period can be attributed to advancements in automated sterility testing technologies, expansion of outsourcing testing services, integration of ai and digital monitoring tools, increasing adoption of rapid microbiological methods, growing regulatory mandates for biologics and gene therapies. Major trends in the forecast period include rising demand for in-house and outsourced sterility testing services, growing adoption of bioburden and endotoxin testing in pharmaceutical manufacturing, increasing use of advanced instruments, kits, and reagents for sterility analysis, expansion of testing services for biologics, vaccines, gene, and cell therapies, enhanced focus on regulatory compliance and quality assurance in sterility testing.

The growth in biologics sales is anticipated to drive the pharmaceutical sterility testing market. Biologics, also known as biological products, are medicines derived from living organisms and include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. Pharmaceutical sterility testing plays a critical role in quality assurance by ensuring that biologics are free from microbial contamination prior to patient administration. For example, in October 2024, according to the Generics and Biosimilars Initiative, a Belgium-based organization that provides scientific information on generic and biosimilar medicines, in addition to the nine leading biologics, two other complex drugs reported strong sales in 2023. Novo Nordisk’s Ozempic (semaglutide) and Eli Lilly’s Trulicity (dulaglutide), both used in the treatment of type 2 diabetes, generated sales of US$14 billion and US$7.2 billion, respectively. As a result, the increasing sales of biologics are contributing to the growth of the pharmaceutical sterility testing market.

Key companies operating in the pharmaceutical sterility testing market are emphasizing the development of innovative solutions, such as advanced biological indicators, to speed up sterility verification, improve testing precision, and enhance overall manufacturing safety. Advanced biological indicators are specialized tools that contain highly resistant microorganisms and are used to quickly and accurately validate the effectiveness of sterilization processes in pharmaceutical production. For instance, in September 2025, Nelson Labs, a US-based contract testing laboratory, introduced the RapidCert Biological Indicator (BI) sterility testing platform. This platform substantially reduces the time required to confirm sterility, improving efficiency in pharmaceutical manufacturing and enabling faster product release while maintaining strict quality standards.

In September 2024, Eurofins Scientific SE, a Luxembourg-based global leader in bioanalytical testing, acquired Infinity Laboratories, LLC, for an undisclosed amount. Through this acquisition, Eurofins seeks to broaden its laboratory service capabilities, strengthen its testing portfolio, expand its regional footprint in the United States, and accelerate service delivery for clients. Infinity Laboratories, LLC, is a US-based contract laboratory specializing in pharmaceutical sterility testing.

Major companies operating in the pharmaceutical sterility testing market are Pacific Biolabs Inc., STERIS Corporation, Boston Analytical Inc., Gibraltar Laboratories Inc., Sartorius AG, Solvias AG, SGS S.A., Toxikon Inc., Pace Analytical Services LLC, Charles River Laboratories International Inc., Nelson Laboratories Inc., Rapid Micro Biosystems Inc., bioMérieux Inc., Merck KGaA, WuXi AppTec, Sotera Health LLC, Dynalabs LLC, Infinity Laboratories, Eurofins Scientific SE, Avomeen Analytical Services, Microbac Laboratories Inc., Analytical Lab Group LLC, North American Science Associates Inc., Medical Device Testing Services Inc., Microtest Laboratories Inc., BioScreen Testing Services Inc., Microchem Laboratory Inc., Bactolac Pharmaceutical Inc., Micro Quality Labs Inc., BioPharma Services Inc., Microbiology Research Associates, BioScience Laboratories Inc.

North America was the largest region in the pharmaceutical sterility testing market in 2025. The Middle East is expected to be the fastest-growing region in the global pharmaceutical sterility testing market share during the forecast period. The regions covered in the pharmaceutical sterility testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical sterility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pharmaceutical sterility testing market by raising the cost of imported instruments, kits, reagents, and laboratory equipment, affecting both in-house and outsourced testing services. Segments like bioburden and endotoxin testing, as well as biologics and gene therapy testing, are most affected, particularly in North America and Europe, which rely heavily on imported high-precision instruments. While tariffs have increased operational costs and caused supply chain delays, they have also promoted local manufacturing, innovation in testing instruments, and development of cost-efficient domestic testing solutions.

The pharmaceutical sterility testing market research report is one of a series of new reports that provides pharmaceutical sterility testing market statistics, including pharmaceutical sterility testing industry global market size, regional shares, competitors with a pharmaceutical sterility testing market share, detailed pharmaceutical sterility testing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical sterility testing industry. This pharmaceutical sterility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical sterility testing is defined as a procedure designed to determine whether biological parenteral products intended for human use contain any extraneous, viable contaminating microorganisms. All pharmaceutical products administered to patients by healthcare professionals must meet the highest standards of quality and safety, as any compromise could cause harm to patients. Sterility testing ensures that the product being offered is appropriately sterile.

The primary types of pharmaceutical sterility testing include in-house and outsourced approaches. The different testing methods include sterility testing, bioburden testing, and bacterial endotoxin testing, which are applied to sterile drugs, medical devices, biologics, and therapeutics. A bacterial endotoxin test is an in vitro assay used to detect bacterial endotoxins. This test identifies endotoxins by lysing blood cells obtained from horseshoe crabs. The various products utilized include instruments, kits and reagents, and services.

The pharmaceutical sterility testing market includes revenues earned by entities by membrane filtration, direct transfer (product immersion), and product flush. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.